1. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. (January 2017) Authors: Trusheim, John; Dunbar, Erin; Battiste, James; Iwamoto, Fabio; Mohile, Nimish; Damek, Denise; Bota, Daniela A; Connelly, Jennifer Journal: CNS oncology Issue: Volume 6:Number 1(2017) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. Issue 3 (26th October 2022) Authors: Brastianos, Priscilla K.; Twohy, Erin L.; Gerstner, Elizabeth R.; Kaufmann, Timothy J.; Iafrate, A. John; Lennerz, Jochen; Jeyapalan, Suriya; Piccioni, David E.; Monga, Varun; Fadul, Camilo E.; Schiff, David; Taylor, Jennie W.; Chowdhary, Sajeel A.; Bettegowda, Chetan; Ansstas, George; De La Fuen... Journal: Journal of clinical oncology Issue: Volume 41:Issue 3(2023) Page Start: 618 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CTNI-03. EXTENDED BENEFITS IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA THAT CONTINUOUSLY RECEIVE TOCA FC AFTER TOCA 511 TREATMEN. (12th November 2021) Authors: Walbert, Tobias; Damek, Denise; Nina, L Martinez; Piccioni, David; Singer, Samuel; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM). (14th November 2022) Authors: Wen, Patrick Y; de Groot, John; Battiste, James; Goldlust, Samuel; Damek, Denise; Ellingson, Benjamin; Garner, James; Friend, John; Simpson, Jeremy; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CTNI-44. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/mTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER. (9th November 2020) Authors: Wen, Patrick; de Groot, John; Battiste, James; Goldlust, Samuel; Damek, Denise; Garner, James; Simpson, Jeremy; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DDIS-26. HIGH-THROUGHPUT DRUG SCREENING OF MENINGIOMAS IDENTIFIES HDAC INHIBITORS AS PROMISING TARGETS ACROSS GRADES. (11th November 2019) Authors: Tatman, Philip; Fringuello, Anthony; Wroblewski, Teddy; Scherer, Sam; Foreman, William; Ryan Ormond, D; Damek, Denise; Lillehei, Kevin; Jensen, Randy; Graner, Michael Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DDRE-10. SCREENING OF EPIGENETIC COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS FOR THEIR POTENTIAL TREATMENT. (12th November 2021) Authors: Tatman, Philip; Wroblewski, Tadeusz; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DDRE-20. HIGH-THROUGHPUT SCREENING OF FDA-APPROVED COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS. (12th November 2021) Authors: Wroblewski, Tadeusz; Tatman, Philip; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DDRE-43. SCREENING OF FDA-APPROVED COMPOUNDS FOR THE TREATMENT OF CHORDOMA, WITH IN VIVO VALIDATION USING THREE DIFFERENT XENOGRAFT MODELS, IDENTIFIES BRIGATINIB AS A POTENTIAL TREATMENT. (12th November 2021) Authors: Tatman, Philip; Wroblewski, Tadeusz; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DDRE-45. HIGH-THROUGHPUT SCREENING OF EPIGENETIC COMPOUNDS FOR THE TREATMENT OF CHORDOMA IDENTIFIES POTENTIAL NOVEL THERAPEUTICS. (12th November 2021) Authors: Wroblewski, Tadeusz; Tatman, Philip; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗